Sartorius Stedim H1 FY26 net income rises 17.6% to EUR 181.1 million; revenue climbs 2.5% to EUR 1.53 billion

• Sartorius Stedim Biotech first-half revenue rose 2.5% to EUR 1.53 billion.
• Current EBITDA increased 3.7% to EUR 478.9 million; margin widened 0.4 percentage point to 31.4%.
• Net profit climbed 17.6% to EUR 181.1 million, while operating profit advanced to EUR 303.2 million.
• Operating cash flow grew 39.4% to EUR 341.2 million; free cash flow more than doubled to EUR 198.8 million.
• Management confirmed its 2026 outlook, guiding constant-currency revenue growth of about 6%-10% with current EBITDA margin slightly above 31%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sartorius Stedim Biotech SA published the original content used to generate this news brief on July 23, 2026, and is solely responsible for the information contained therein.